hyperaldosteronism: Overproduction of aldosterone by the adrenal glands, which may lead to hypokalemia and/or hypernatremia. [ NCIT:P378 ]
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
1162 |
4. Check minimum number of eventsNone |
1162 |
5. Include endpointsNone |
1162 |
6. Filter based on genotype QC (FinnGen only) |
1045 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E20-E35
- Name in latin
- Hyperaldosteronismus
Similar endpoints
↥List of similar endpoints to
Hyperaldosteronism
based on the number of shared cases.
Similar with more cases:
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5523 | 2949 | 2543 |
| Only index persons | 5035 | 2705 | 2330 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.08 | 0.08 | 0.07 |
| Only index persons | 0.09 | 0.10 | 0.09 |
| Median age at first event (years) | |||
| Whole population | 57.31 | 56.48 | 58.24 |
| Only index persons | 56.72 | 55.67 | 57.95 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1045 | 572 | 473 |
| Unadjusted period prevalence (%) | 0.21 | 0.20 | 0.22 |
| Median age at first event (years) | 57.47 | 55.64 | 59.67 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 1088
- Matched controls
- 10880
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
184.7
322.5
158
10
C03DA01
ATC
spironolactone; oral
70.2
307.7
923
803
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
54.4
307.7
239
56
BC1AD
NOMESCO Finland
CT of adrenal glands
56.2
307.7
187
40
E26.0
ICD-10 Finland
Primary hyperaldosteronism
14403.7
307.7
863
*
A12BA01
ATC
potassium chloride; oral
18.8
299.4
258
177
E87.6
ICD-10 Finland
Hypokalaemia
16.3
280.2
262
208
E26.9
ICD-10 Finland
Hyperaldosteronism, unspecified
+∞
243.1
224
*
205
Kela drug reimbursment
Chronic hypertension
7.0
230.3
651
1904
BC4WT
NOMESCO Finland
Selective blood sample from adrenal gland with radiological guidance
+∞
210.4
195
*
C02AC05
ATC
moxonidine; oral
10.2
172.3
214
254
I15.2
ICD-10 Finland
Hypertension secondary to endocrine disorders
593.8
159.2
154
*
I15.9
ICD-10 Finland
Secondary hypertension, unspecified
34.2
141.6
91
29
C08CA01
ATC
amlodipine; oral
5.0
141.3
741
3263
E260, I152,
ICD-10 Finland
+∞
136.4
128
*
I10
ICD-10 Finland
Essential (primary) hypertension
7.0
114.6
962
5691
BC1CD
NOMESCO Finland
Very extensive CT of adrenal glands
63.4
108.0
60
10
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
4.2
93.5
320
979
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
9.7
90.9
111
126
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
18.8
85.9
69
39
C08CA13
ATC
lercanidipine; oral
4.0
85.7
321
1040
C08CA02
ATC
felodipine; oral
4.7
83.6
228
583
C08CA05
ATC
nifedipine; systemic
5.1
59.5
136
297
C07AG02
ATC
carvedilol; oral
4.8
58.4
144
335
C07AB07
ATC
bisoprolol; oral
2.8
55.6
693
4232
E26.8
ICD-10 Finland
Other hyperaldosteronism
+∞
49.3
47
*
2551A
ICD-9 Finland
Disorders of adrenal glands, Hyperaldosteronism
+∞
47.2
45
*
E26.1
ICD-10 Finland
Secondary hyperaldosteronism
+∞
46.2
44
*
E26
ICD-10 Finland
Hyperaldosteronism
+∞
45.1
43
*
C09AA02
ATC
enalapril; systemic
2.7
44.2
306
1367
C07AB02
ATC
metoprolol; systemic
2.7
42.0
300
1358
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.0
40.6
123
333
C09BA02
ATC
enalapril and diuretics; systemic
3.5
39.9
150
471
4019X
ICD-9 Finland
Essential hypertension, Unspecified
6.3
38.8
67
112
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.4
38.3
361
1850
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.4
37.8
369
1919
103
Kela drug reimbursment
Diabetes, insulin-treated
2.3
35.1
382
2070
XF602
NOMESCO Finland
Bloodpressure monitoring
10.1
34.9
40
41
C09CA01
ATC
losartan; oral
2.3
33.5
372
2025
C08DB01
ATC
diltiazem; oral
4.0
33.1
98
260
BCA30
NOMESCO Finland
Unilateral adrenalectomy
336.9
33.1
33
*
C03DB01
ATC
amiloride; oral
49.1
31.7
38
8
E21.0
ICD-10 Finland
Primary hyperparathyroidism
49.1
31.7
38
8
T90
ICPC
Diabetes non-insulin dependent
2.2
30.8
350
1913
C08CA03
ATC
isradipine; systemic
9.8
30.7
36
38
A10BA02
ATC
metformin; oral
2.2
30.7
395
2266
C03BA11
ATC
indapamide; oral
5.3
30.7
64
128
K85
ICPC
Elevated blood pressure
2.3
29.0
264
1310
C09CA03
ATC
valsartan; oral
2.8
28.8
163
645
C03AA03
ATC
hydrochlorothiazide; oral
3.0
28.6
143
529
G47.3
ICD-10 Finland
Sleep apnoea
2.2
28.0
329
1811
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.4
27.9
239
1153
C09DA01
ATC
losartan and diuretics; oral
2.7
27.4
174
729
40199
ICD-8 Finland
Essential benign hypertension
7.0
27.3
42
62
C02LM02, ,
ATC
7.9
26.9
37
48
C07FB02
ATC
metoprolol and felodipine; systemic
4.9
26.7
60
128
C08CA10
ATC
nilvadipine; oral
5.8
25.9
48
86
C02EA02, ,
ATC
4.1
25.8
73
187
25500
ICD-8 Finland
Diseases of adrenal glands, Aldosteronismus. Syndroma Conn
+∞
25.1
24
*
C09CA06
ATC
candesartan; oral
2.1
24.5
329
1890
C07AB08
ATC
celiprolol; oral
5.1
24.4
52
106
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
88.8
23.7
26
*
I152, E260,
ICD-10 Finland
+∞
23.0
22
*
C02CA01
ATC
prazosin; oral
7.5
23.0
33
45
C07AB03
ATC
atenolol; systemic
3.3
22.4
91
297
I11.9
ICD-10 Finland
Hypertensive heart disease without (congestive) heart failure
3.6
22.4
78
231
C09DA07
ATC
telmisartan and diuretics; oral
3.7
22.0
71
200
N18.8
ICD-10 Finland
Other chronic renal failure
5.4
21.9
44
85
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.1
21.6
252
1365
C09CA07
ATC
telmisartan; oral
2.8
21.4
115
441
C02DE02, ,
ATC
7.4
21.3
31
43
C09DA06
ATC
candesartan and diuretics; oral
2.7
21.0
121
481
WX402
NOMESCO Finland
General anaesthesia
2.0
20.4
285
1645
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
19.8
19
*
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
3.7
19.7
63
176
ZXD10
NOMESCO Finland
Scheduled procedure
1.8
19.6
438
2935
C03CA01
ATC
furosemide; systemic
1.9
19.6
353
2212
C02DE10, ,
ATC
7.2
19.6
29
41
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
2.8
19.3
100
375
O10.0
ICD-10 Finland
Pre-existing essential hypertension complicating pregnancy, childbirth and the puerperium
7.7
19.2
27
36
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
5.2
19.1
40
80
I15.8
ICD-10 Finland
Other secondary hypertension
23.0
19.1
27
12
207
Kela drug reimbursment
Chronic arrhythmias
2.1
19.1
212
1123
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
18.9
576
4218
ZXE10
NOMESCO Finland
More than one and less than three hours
1.8
18.8
415
2763
SPAT1262
SPAT
Handing over of treatment supplies
2.1
18.5
223
1215
Z3231
NOMESCO Finland
Registered nurse
1.9
18.1
318
1969
E66.00
ICD-10 Finland
Metabolic syndrome
2.9
17.9
89
327
BC1BD
NOMESCO Finland
Extensive CT of adrenal glands
67.8
17.8
20
*
A10BH05
ATC
linagliptin; oral
2.9
17.6
85
307
346
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
2.8
17.4
92
349
A11CC03
ATC
alfacalcidol; systemic
4.7
17.4
40
87
C09DB01
ATC
valsartan and amlodipine; oral
3.5
17.3
62
187
ZXE00
NOMESCO Finland
One hour or less
1.7
16.7
436
3021
A12AA04
ATC
calcium carbonate; oral
6.6
16.7
27
42
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
2.2
16.6
156
771
A10BK03
ATC
empagliflozin; oral
2.2
16.6
154
758
A10BH01
ATC
sitagliptin; oral
2.3
16.3
132
613
K86
ICPC
Hypertension uncomplicated
2.0
15.8
188
1017
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
5.4
15.7
31
59
E66.01
ICD-10 Finland
Obesity due to excess calories
2.4
15.6
119
538
A10BJ06
ATC
semaglutide; parenteral
2.7
15.5
85
329
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
38.7
15.4
19
5
C08DA01
ATC
verapamil; systemic
3.1
15.4
66
223
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
1.8
14.9
308
1984
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
2.9
14.9
70
249
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
+∞
14.6
14
*
B01AA03
ATC
warfarin; systemic
1.9
14.4
214
1245
C09DA03
ATC
valsartan and diuretics; oral
2.8
14.3
74
277
R53
ICD-10 Finland
Malaise and fatigue
1.8
14.2
293
1884
PC5CG
NOMESCO Finland
Extensive MRI examination of kidney vasculature with high intensity magnet
43.1
14.1
17
*
H02AB09
ATC
hydrocortisone; systemic
5.0
14.1
30
61
C02DE04, ,
ATC
4.4
13.9
35
82
2533
FHL
Unilateral removal of additional egg
+∞
13.6
13
*
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
2.7
13.6
77
303
I12.0
ICD-10 Finland
Hypertensive renal disease with renal failure
6.4
13.3
22
35
Z2221
NOMESCO Finland
Medical doctor
1.7
13.3
302
1990
E87.5
ICD-10 Finland
Hyperkalaemia
4.3
13.2
34
81
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
1.9
13.2
209
1238
TFP20
NOMESCO Finland
Cardiodefibrillation
2.3
13.2
102
464
TPH07
NOMESCO Finland
Cathetrisation of artery
2.0
13.1
145
761
E66.8
ICD-10 Finland
Other obesity
2.7
13.1
71
273
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
1.9
12.7
188
1090
M04AA01
ATC
allopurinol; systemic
2.0
12.6
156
852
C09DX01
ATC
valsartan, amlodipine and hydrochlorothiazide; oral
3.9
12.5
37
98
R4110
NOMESCO Finland
Physiotherapy
1.7
12.5
317
2145
TPH04
NOMESCO Finland
Cathetrisation of vein
1.7
12.4
259
1662
I48
ICD-10 Finland
Atrial fibrillation and flutter
1.8
12.4
245
1548
R35
ICD-10 Finland
Polyuria
2.3
12.2
95
433
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.6
12.1
385
2754
C07AB04
ATC
acebutolol; systemic
4.7
11.9
27
58
R06.0
ICD-10 Finland
Dyspnoea
1.7
11.9
313
2133
XF404
NOMESCO Finland
Ambulatory ECG
2.2
11.9
111
545
C07BB07
ATC
bisoprolol and thiazides; systemic
2.9
11.9
55
194
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.1
11.9
117
587
C07AB12
ATC
nebivolol; oral
3.1
11.9
49
162
XF400
NOMESCO Finland
ECG with 12 standard connections
1.9
11.9
178
1035
R5140
NOMESCO Finland
Monitoring the use of the aid
2.0
11.8
144
781
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
2.9
11.6
54
191
C07AB05
ATC
betaxolol; oral
3.5
11.6
40
118
I11.0
ICD-10 Finland
Hypertensive heart disease with (congestive) heart failure
3.4
11.6
42
128
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
15.2
11.3
18
12
J01MA02
ATC
ciprofloxacin; systemic
1.6
11.3
417
3079
321
Kela drug reimbursment
Paricalcitol and cinacalcet
35.4
11.3
14
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
3.2
11.2
44
141
R55
ICD-10 Finland
Syncope and collapse
2.0
11.1
133
717
N02BE01
ATC
paracetamol; systemic, rectal
2.0
11.1
980
8897
A10AE04
ATC
insulin glargine; parenteral
2.0
11.1
118
610
WX110
NOMESCO Finland
Infiltration anesthesia
1.6
11.0
764
6481
P06
ICPC
Sleep disturbance
1.9
10.9
150
847
R07.4
ICD-10 Finland
Chest pain, unspecified
1.6
10.5
323
2278
C03EA02
ATC
trichlormethiazide and potassium-sparing agents; oral
4.1
10.5
28
69
R60.0
ICD-10 Finland
Localized oedema
1.9
10.4
147
836
E24.8
ICD-10 Finland
Other Cushing syndrome
+∞
10.4
10
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
1.7
10.3
222
1429
XF600
NOMESCO Finland
Bloodpressure measurement
2.3
10.3
76
339
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
3.9
10.2
29
75
M10.9
ICD-10 Finland
Gout, unspecified
2.2
10.0
89
430
KA1AE
NOMESCO Finland
Kidney ultrasound examination
3.2
9.9
38
120
C10AA01
ATC
simvastatin; oral
1.5
9.8
452
3475
B01AF02
ATC
apixaban; oral
1.8
9.8
161
961
K76.0
ICD-10 Finland
Fatty (change of) liver, not elsewhere classified
3.0
9.7
41
138
Z3226
NOMESCO Finland
Physiotherapist
1.7
9.7
194
1225
C02EA03, ,
ATC
4.4
9.6
24
56
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.8
9.6
161
965
N02AX02
ATC
tramadol; systemic, rectal
1.5
9.4
461
3582
Z01.8
ICD-10 Finland
Other specified special examinations
1.6
9.4
246
1663
I50.9
ICD-10 Finland
Heart failure, unspecified
1.8
9.4
151
895
I48.1
ICD-10 Finland
Persistent atrial fibrillation
2.5
9.3
57
233
Z49.1
ICD-10 Finland
Extracorporeal dialysis
5.0
9.3
20
41
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
5.0
9.3
20
41
XKD00
NOMESCO Finland
Uroflowmetry
1.7
9.3
168
1030
R04.0
ICD-10 Finland
Epistaxis
2.1
9.3
94
477
A10AB05
ATC
insulin aspart; parenteral
2.1
9.1
88
438
H05BX01
ATC
cinacalcet; oral
37.0
9.0
11
*
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
2.2
9.0
74
346
N05BA04
ATC
oxazepam; oral
1.6
8.9
279
1965
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
8.0
8.9
19
24
C09BA03
ATC
lisinopril and diuretics; oral
3.2
8.8
34
108
WX408
NOMESCO Finland
General anesthesy, balanced
1.6
8.8
270
1891
WX723
NOMESCO Finland
CPAP therapy
2.5
8.7
56
235
A02BC02
ATC
pantoprazole; systemic
1.5
8.6
734
6322
A10BB12
ATC
glimepiride; oral
2.1
8.6
77
373
ZXA10
NOMESCO Finland
Bilateral
1.6
8.6
198
1295
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
2.1
8.5
80
394
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.5
8.5
353
2637
K87
ICPC
Hypertension complicated
2.9
8.4
39
138
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.6
8.4
266
1873
J01DB01
ATC
cefalexin; oral
1.6
8.4
874
7829
D350, E260,
ICD-10 Finland
+∞
8.3
8
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
8.3
8
*
N19
ICD-10 Finland
Unspecified kidney failure
2.6
8.3
48
191
A10BK01
ATC
dapagliflozin; oral
2.0
8.3
95
504
U14
ICPC
Kidney symptom/complaint
3.9
8.3
24
63
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
7.1
8.3
19
27
8260/3-C73.9
ICD-O-3
Papillary adenocarcinoma, NOS, of thyroid gland
4.4
8.2
20
46
J45.9
ICD-10 Finland
Asthma, unspecified
1.6
8.1
203
1352
WX006
NOMESCO Finland
Intravenous sedation or analgesia without general anesthesia
2.1
8.1
80
402
A06AC01
ATC
ispaghula (psylla seeds); oral
1.5
8.1
287
2071
I15
ICD-10 Finland
Secondary hypertension
17.3
8.1
12
7
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
1.6
7.9
179
1164
JN3AD
NOMESCO Finland
Abdominal CT examination
1.7
7.8
147
909
UJF30
NOMESCO Finland
Ileoscopy through colon
1.8
7.8
118
686
C09AA04
ATC
perindopril; oral
2.3
7.7
58
261
WX892
NOMESCO Finland
Monitored bed care
2.0
7.7
87
459
C09CA08
ATC
olmesartan medoxomil; oral
3.3
7.7
28
86
C03EB01
ATC
furosemide and potassium-sparing agents; systemic
2.7
7.7
41
157
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
2.5
7.7
49
205
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
2.6
7.6
44
176
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
1.9
7.6
103
579
TK800
NOMESCO Finland
Hemodialysis
3.4
7.6
26
77
R42
ICD-10 Finland
Dizziness and giddiness
1.5
7.5
245
1733
WZC00
NOMESCO Finland
Treatment plan or consultation
1.5
7.5
379
2929
A91
ICPC
Abnormal result investigation NOS
2.1
7.5
69
338
I48.0
ICD-10 Finland
Paroxysmal atrial fibrillation
1.8
7.5
105
596
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
3.9
7.5
21
54
Z71.8
ICD-10 Finland
Other specified counselling
1.5
7.4
349
2658
UKC02
NOMESCO Finland
Cystoscopy
1.6
7.4
167
1083
I48.9
ICD-10 Finland
Atrial fibrillation and atrial flutter, unspecified
1.9
7.4
89
481
N06AX11
ATC
mirtazapine; oral
1.5
7.3
352
2692
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
1.8
7.3
117
691
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
7.3
7
*
BA1AE
NOMESCO Finland
Thyroiid ultrasound examination
3.5
7.3
24
69
RD210, ,
NOMESCO Finland
4.2
7.3
19
46
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
2.3
7.3
54
242
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
1.5
7.2
249
1780
C09AA03
ATC
lisinopril; oral
2.3
7.2
55
250
WZC30
NOMESCO Finland
Teaching
1.6
7.2
182
1215
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
1.7
7.1
143
899
C07AA07
ATC
sotalol; systemic
2.6
7.1
41
164
C09AA05
ATC
ramipril; oral
1.5
7.1
270
1972
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
1.6
7.0
165
1080
C10AA05
ATC
atorvastatin; oral
1.4
7.0
459
3705
S18
ICPC
Laceration/cut
1.4
7.0
505
4145
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
3.0
7.0
30
102
H03AA01
ATC
levothyroxine sodium; systemic
1.5
7.0
226
1593
104
Kela drug reimbursment
Thyroid insufficiency
2.0
6.9
75
390
M54.5
ICD-10 Finland
Low back pain
1.4
6.9
379
2962
E78.29
ICD-10 Finland
Other mixed hyperlipidaemia
5.9
6.9
18
31
L03
ICPC
Low back symptom/complaint
1.5
6.9
302
2266
T99
ICPC
Endocr/metab/nutrit disease other
3.3
6.9
25
77
WX780
NOMESCO Finland
Remote monitoring CPAP
2.2
6.8
55
256
Z3229
NOMESCO Finland
Other healthcare associate professional
1.9
6.8
87
480
K78
ICPC
Atrial fibrillation/flutter
1.9
6.7
88
488
D07AC01
ATC
betamethasone; topical
1.4
6.7
367
2868
N06AA09
ATC
amitriptyline; systemic
1.8
6.7
99
572
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
6.5
6.6
16
25
L28
ICPC
Limited function/disability (L)
1.5
6.6
197
1362
M54.9
ICD-10 Finland
Dorsalgia, unspecified
1.7
6.6
131
821
S97
ICPC
Chronic ulcer skin
2.0
6.6
75
397
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
2.0
6.6
69
355
SPAT1336
SPAT
Request for examination
2.5
6.6
41
170
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
1.6
6.4
142
915
WX002
NOMESCO Finland
Sedation and analgesia
1.5
6.4
197
1371
A46
ICD-10 Finland
Erysipelas
1.6
6.4
153
1006
A01
ICPC
Pain general/multiple sites
1.7
6.4
113
687
Z76.0
ICD-10 Finland
Issue of repeat prescription
1.5
6.4
274
2044
N06CA01
ATC
amitriptyline and psycholeptics; systemic
1.8
6.3
103
611
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
2.3
6.3
44
192
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
1.8
6.3
93
536
J34.1
ICD-10 Finland
Cyst and mucocele of nose and nasal sinus
3.5
6.3
21
61
S29
ICPC
Skin symptom/complaint other
1.5
6.3
211
1497
N06AX21
ATC
duloxetine; oral
1.7
6.3
125
785
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
1.7
6.3
119
738
E260, D350,
ICD-10 Finland
+∞
6.3
6
*
E27.0
ICD-10 Finland
Other adrenocortical overactivity
+∞
6.3
6
*
BBA20
NOMESCO Finland
Exploration of parathyroid gland
+∞
6.3
6
*
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
6.3
6
*
I48.2
ICD-10 Finland
Chronic atrial fibrillation
2.1
6.2
58
287
K80.2
ICD-10 Finland
Calculus of gallbladder without cholecystitis
1.7
6.2
118
733
I50
ICD-10 Finland
Heart failure
2.5
6.2
36
145
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
1.5
6.2
176
1206
I15.0
ICD-10 Finland
Renovascular hypertension
7.7
6.1
13
17
N17.9
ICD-10 Finland
Acute renal failure, unspecified
2.2
6.1
47
215
G04CA02
ATC
tamsulosin; oral
1.5
6.1
236
1724
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
10.1
6.0
11
11
C02DE12, ,
ATC
5.6
6.0
16
29
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
402
114
55.34
307.65
3.0
1.2
1178.20
300.00
pmol/l
2.14
388
103
287
34
114.30
307.65
1.4
1.2
184.80
159.17
mmol/24h
0.90
287
34
221
114
24.07
293.10
1.3
1.2
0.56
16.48
nmol/l
0.50
210
107
223
118
23.51
292.52
1.3
1.2
0.31
0.42
nmol/l
—
13
5
202
97
25.34
275.52
1.3
1.2
0.18
0.17
nmol/l
0.36
146
78
180
98
21.81
231.77
1.3
1.2
—
—
nmol/l
—
0
0
84
25
36.33
133.24
1.8
1.1
746.92
373.94
pmol/l
2.81
63
17
92
39
25.68
129.95
1.7
1.5
3.34
1.42
nmol/l
0.89
76
34
75
19
42.32
124.03
1.5
1.1
86.88
71.89
nmol/24h
0.46
75
19
342
908
5.03
123.34
2.5
2.0
325.50
380.27
nmol/l
4.65
326
852
454
1716
3.82
98.52
3.2
3.3
0.82
0.82
mmol/l
0.15
432
1636
88
84
11.31
81.42
1.8
1.2
26.78
23.56
ng/l
0.22
88
84
804
5068
3.25
65.22
10.0
7.2
1.21
1.21
mmol/l
1.14
694
4395
735
4552
2.89
58.68
9.5
6.5
1.21
1.21
mmol/l
1.51
709
4214
603
3458
2.67
54.61
5.1
4.1
12.67
8.62
mg/mmol
1.22
408
2195
603
3535
2.58
50.99
4.1
3.3
7.13
7.67
mmol/l
2.27
524
3000
202
704
3.30
45.79
5.9
3.2
109.29
83.17
ng/l
3.03
183
619
299
1322
2.74
44.07
9.1
5.6
1.04
1.05
mmol/l
0.05
283
1228
711
4752
2.43
41.71
19.9
15.4
1.28
1.25
inr
0.49
628
3952
679
4466
2.38
41.03
6.1
5.1
36.42
35.56
g/l
4.50
640
4202
487
2835
2.30
38.49
4.0
3.3
0.44
0.46
e6/l
0.07
356
2093
656
4394
2.24
35.93
14.5
11.8
0.00
0.00
e9/l
1.25
563
3597
531
3296
2.19
34.85
4.1
3.4
65.22
79.78
e6/l
0.14
407
2537
578
3730
2.17
34.11
4.7
4.0
119.04
102.71
e6/l
0.08
419
2643
59
102
6.06
33.01
1.7
1.9
5.09
4.59
mmol/24h
0.46
54
95
227
1044
2.48
29.63
4.9
3.5
1.50
1.92
mmol/l
0.69
202
889
227
1086
2.38
26.94
4.9
3.4
5.87
5.80
kpa
0.46
222
1052
778
5908
2.11
26.77
6.6
5.3
6.98
6.71
mmol/l
2.54
750
5641
202
920
2.47
26.72
10.5
7.0
10.72
9.92
mmol/l
0.70
194
889
96
300
3.41
25.42
3.3
3.4
1.64
1.54
mg/l
0.34
87
269
376
2279
1.99
24.00
3.3
2.7
3.71
5.34
e6/l
2.59
346
2086
409
2555
1.96
23.89
4.5
4.2
87.73
89.23
%
0.52
403
2509
918
7566
2.37
23.86
10.0
8.4
77.56
79.82
u/l
0.96
892
7191
614
4452
1.87
22.14
3.2
2.4
76.73
77.69
nmol/l
0.36
566
3991
412
2661
1.88
21.17
3.3
2.8
370.09
344.36
umol/l
4.81
360
2343
506
3486
1.84
21.17
3.6
3.5
2.36
2.35
mmol/l
1.23
466
3161
66
190
3.63
19.77
5.9
4.1
3.08
2.71
mmol/l
0.38
49
132
694
5338
1.83
19.57
6.3
6.9
12.14
11.65
umol/l
0.34
666
5121
1022
9063
3.10
19.21
9.4
6.5
40.83
39.45
mmol/mol
4.82
982
8495
163
776
2.29
19.13
6.0
3.8
1.22
1.22
mmol/l
0.24
150
668
488
3399
1.79
19.08
3.1
3.3
32.36
33.91
u/l
0.28
458
3214
259
1488
1.97
18.56
4.4
2.5
23.01
22.75
%
0.12
246
1399
884
7431
2.01
17.90
5.4
4.2
15.03
14.80
pmol/l
2.03
822
6832
720
5679
1.79
17.80
9.1
10.1
4.49
4.16
e9/l
3.38
617
4954
271
1607
1.91
17.56
4.2
2.5
2.30
2.29
g/l
0.05
252
1498
916
7830
2.07
17.22
29.7
20.6
13.71
13.67
%
0.37
906
7740
452
3159
1.74
16.86
3.6
3.2
1754.38
1182.88
ng/l
1.42
386
2727
677
5289
1.74
16.84
4.9
3.9
0.00
0.31
estimate
0.52
176
1018
673
5256
1.74
16.69
4.9
3.9
0.01
4.53
estimate
1.07
192
1085
176
912
2.11
16.62
4.0
3.0
4.85
4.48
kpa
1.45
170
883
270
1631
1.87
16.39
3.5
3.1
1.84
2.24
e6/l
0.33
122
815
290
1793
1.84
16.34
3.4
2.9
0.66
1.10
e6/l
2.54
145
979
665
5193
1.72
16.33
4.8
3.9
0.01
0.00
estimate
0.38
190
1066
280
1729
1.83
15.77
4.2
2.5
13.02
12.89
umol/l
0.11
265
1618
857
7266
1.85
15.04
5.3
4.4
13.37
12.38
mm/h
0.95
815
6799
771
6380
1.72
14.23
5.9
4.8
579.00
2454.74
e6/l
—
6
101
1014
9179
2.54
14.11
28.5
15.9
74.34
80.05
ml/min/173m2
12.80
972
8539
301
1966
1.73
13.73
4.7
4.1
139.07
346.46
ng/l
2.83
250
1562
984
8815
2.22
13.70
6.8
5.3
1.97
1.93
mu/l
0.30
929
8160
177
982
1.96
13.69
2.6
2.6
32.22
41.71
u/l
1.15
147
828
60
207
3.01
13.48
3.1
2.7
17.83
15.96
%
3.55
60
201
310
2055
1.71
13.35
3.2
3.0
2.46
2.45
mmol/l
0.40
275
1845
70
273
2.67
12.55
2.8
3.2
1.35
1.84
index
0.33
34
146
1047
9700
3.11
12.54
35.6
19.6
139.57
139.68
mmol/l
0.72
1037
9518
1023
9375
2.53
12.46
23.9
16.7
22.13
24.79
mg/l
2.07
902
7793
112
543
2.18
12.42
3.3
3.4
4.35
4.46
pmol/l
0.62
101
484
1011
9226
2.35
12.28
6.8
5.3
6.30
5.98
mmol/l
8.85
952
8476
1047
9717
3.06
12.17
37.2
19.8
3.88
3.98
mmol/l
22.43
1037
9517
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
75
308
2.54
12.12
2.5
2.5
0.34
0.36
iu/ml
0.10
37
170
83
359
2.42
12.01
2.8
2.8
24.27
24.97
mmol/l
0.82
83
353
159
889
1.92
11.94
2.9
3.1
66.57
66.67
g/l
0.06
143
825
542
4212
1.57
11.92
2.1
1.9
1.59
1.35
mmol/l
6.34
462
3566
115
573
2.13
11.89
4.3
3.6
2.41
1.85
mmol/l
0.63
79
437
387
2794
1.60
11.61
4.3
3.4
1.53
0.04
estimate
0.48
164
849
129
679
2.02
11.52
4.4
3.6
5.05
5.16
kpa
0.77
122
659
202
1240
1.77
11.21
8.4
8.5
5.20
5.11
kpa
0.60
197
1198
202
1240
1.77
11.21
8.4
8.5
12.13
12.01
kpa
0.13
197
1199
80
361
2.31
10.54
3.1
4.1
36.96
84.05
mg/l
0.82
66
311
198
1230
1.75
10.50
8.5
8.5
0.84
1.06
mmol/l
0.24
167
1014
424
3197
1.53
10.18
2.5
2.2
178.50
228.65
u/l
0.88
407
3047
74
328
2.35
10.16
3.2
3.9
1.51
2.14
ratio
1.19
43
188
566
4540
1.51
10.13
2.3
2.2
95.34
96.07
pmol/l
0.14
307
2422
144
822
1.87
10.09
2.9
2.2
11.98
13.30
nmol/l
0.44
127
741
79
362
2.27
10.05
3.2
4.1
46.75
62.16
mg/l
0.42
65
311
59
237
2.57
10.00
2.1
2.3
140.44
128.06
g/l
2.96
48
186
192
1202
1.73
9.87
2.8
4.5
232.49
250.00
u/l
1.08
175
1144
575
4663
1.49
9.53
2.9
2.9
—
—
estimate
—
0
0
313
2238
1.56
9.41
1.8
1.7
0.85
1.24
mg/l
3.07
233
1746
186
1169
1.71
9.40
2.8
2.8
6.50
8.22
umol/l
0.77
160
1037
23
53
4.41
9.36
1.7
1.5
86.92
96.67
ng/l
0.28
23
53
494
3908
1.48
9.12
5.1
3.9
38.76
63.44
ng/l
0.72
373
2837
388
2925
1.51
9.07
5.0
4.0
0.01
0.01
estimate
0.03
180
987
121
682
1.87
8.80
11.7
10.7
0.59
0.64
%
0.74
121
677
397
3030
1.49
8.64
1.8
1.7
18.27
20.32
nmol/l
2.63
352
2556
116
650
1.88
8.59
1.7
1.7
—
—
—
0
0
415
3218
1.47
8.24
3.0
2.7
59.61
63.05
u/l
0.52
384
2997
134
798
1.77
8.15
2.9
3.1
269.71
192.31
ng/l
0.66
128
735
273
1954
1.53
7.98
1.5
1.6
2.42
2.55
g/l
0.67
166
1213
55
239
2.37
7.93
2.7
2.4
114.09
75.74
ug/min
0.34
34
145
84
434
2.01
7.89
2.1
2.1
42.04
39.73
u/l
0.53
72
391
250
1766
1.54
7.74
2.0
2.0
—
—
—
0
0
489
3946
1.43
7.71
4.9
3.9
0.02
0.03
estimate
0.05
162
887
120
710
1.78
7.45
11.7
10.3
1.21
1.28
%
0.34
120
704
158
1012
1.66
7.36
2.1
2.3
0.23
0.21
g/l
2.01
144
949
553
4587
1.42
7.36
4.4
3.0
142.42
134.83
ug/l
0.41
516
4277
73
374
2.02
7.04
3.4
2.7
10.75
10.60
g/l
0.08
64
339
293
2185
1.47
6.88
1.3
1.3
0.94
1.44
u/ml
0.74
76
616
87
478
1.89
6.86
1.7
1.8
1.56
1.56
g/l
0.00
75
420
1015
9563
1.91
6.81
7.4
6.0
2.49
2.69
mmol/l
11.02
958
8891
80
430
1.93
6.74
3.2
2.6
3.83
3.78
g/l
0.13
71
398
80
431
1.92
6.69
3.2
2.6
7.63
7.45
g/l
0.42
72
398
80
431
1.92
6.69
3.3
2.6
4.18
4.23
g/l
0.23
72
398
156
1021
1.62
6.65
4.8
3.3
—
—
—
0
0
193
1330
1.55
6.60
1.8
1.9
—
—
—
0
0
1050
10029
2.34
6.54
37.7
21.6
91.46
77.99
umol/l
11.15
1043
9924
1044
9949
2.22
6.54
16.4
12.5
32.95
26.15
u/l
0.86
1024
9671
964
8977
1.65
6.39
5.2
4.4
1.50
1.30
mmol/l
10.48
894
8245
63
318
2.04
6.35
3.2
2.8
0.00
0.00
g/l
-0.00
56
278
15
23
6.60
6.34
1.0
1.1
0.60
0.71
umol/24h
—
7
15
997
9372
1.76
6.32
6.4
5.1
1.31
1.46
mmol/l
27.85
937
8686
343
2673
1.41
6.25
2.7
2.2
2.74
2.92
mg/l
0.78
296
2300
47
213
2.26
6.21
1.3
1.6
1.35
0.87
nmol/l
1.09
35
181
64
328
2.01
6.19
3.2
2.8
0.00
0.01
g/l
0.80
57
295
46
209
2.25
6.05
2.7
1.6
186.02
214.55
pmol/l
1.24
41
193
31
118
2.67
5.93
1.8
5.5
7.02
7.01
mmol/l
0.01
26
99
45
206
2.24
5.82
2.0
1.2
9.43
9.16
u/l
0.05
39
162
998
9423
1.71
5.70
6.4
5.2
4.32
4.61
mmol/l
15.76
950
8797
180
1262
1.51
5.65
1.8
1.9
—
—
—
0
0
28
104
2.74
5.63
1.1
1.2
51.16
49.41
u/l
0.11
20
94
44
203
2.22
5.60
1.3
1.2
17.86
28.78
u/l
0.88
36
178
29
111
2.66
5.51
1.6
1.2
277.59
278.01
mosm/kgh2o
0.03
22
86
68
379
1.85
5.18
3.2
2.9
0.51
1.42
g/l
1.59
58
331
729
6538
1.35
5.00
3.9
3.4
52.15
51.15
u/l
0.14
701
6149
70
404
1.78
4.78
3.2
2.7
3.08
3.01
g/l
0.21
62
371
35
159
2.24
4.66
1.2
1.3
—
—
—
0
0
18
58
3.14
4.65
1.2
1.2
84.31
82.96
u/l
0.03
13
50
118
800
1.53
4.32
2.8
2.8
58.21
67.38
ml/min/173m2
2.12
73
335
31
139
2.27
4.28
1.2
1.0
—
—
—
0
0
266
2098
1.35
4.27
3.6
3.2
0.76
0.74
ug/l
0.18
183
1343
17
56
3.07
4.25
1.2
1.2
18.92
17.53
u/l
0.09
12
47
117
795
1.53
4.25
2.8
3.0
10.78
10.86
g/l
0.08
106
739
311
2515
1.33
4.22
2.5
2.4
—
—
—
0
0
52
285
1.87
4.22
2.3
2.5
189.53
191.82
%
0.06
47
272
16
51
3.17
4.22
7.9
7.4
4.47
329.92
ug/l
—
8
35
31
140
2.25
4.21
1.4
1.2
2.36
4.43
u/ml
1.44
14
58
32
148
2.20
4.11
1.1
1.1
3.50
28.66
iu/ml
—
8
30
31
144
2.19
3.95
1.4
1.2
1.42
4.44
u/ml
1.18
12
50
12
28
4.32
3.82
1.1
1.0
—
—
—
0
0
78
495
1.62
3.81
1.0
1.1
—
1.10
—
0
5
48
268
1.83
3.71
1.5
2.3
12.71
11.99
mg/l
0.22
39
251
44
242
1.85
3.57
2.0
3.3
28.13
33.60
umol/l
1.24
39
218
626
5630
1.26
3.52
2.9
2.9
—
—
—
0
0
55
326
1.72
3.49
1.7
1.6
8.85
15.24
u/ml
—
10
73
217
1712
1.33
3.43
1.4
1.3
13.61
12.64
u/ml
0.05
78
655
1050
10204
1.83
3.41
37.3
25.4
251.73
248.67
e9/l
0.80
1034
10020
1050
10207
1.82
3.36
37.2
25.3
90.73
91.30
fl
3.78
1043
10104
1050
10208
1.82
3.34
38.4
25.9
40.90
40.33
%
3.17
1043
10097
1050
10208
1.82
3.34
37.3
25.3
4.57
4.48
e12/l
7.11
1030
9996
1050
10209
1.82
3.33
37.4
25.4
7.11
6.74
e9/l
8.38
1031
9992
1050
10211
1.81
3.29
37.6
25.5
137.18
135.23
g/l
4.10
1044
10108
40
220
1.85
3.27
3.5
3.4
0.94
0.82
nmol/l
0.54
34
185
6
7
8.61
3.26
10.2
7.6
5.40
5.23
mmol/l
—
6
7
215
1714
1.32
3.15
2.0
1.7
1225.04
1198.35
nmol/l
0.14
166
1307
16
61
2.65
3.14
1.6
1.5
3.18
7.19
u/l
0.81
11
51
27
133
2.06
3.03
1.6
2.4
33.41
32.61
pg
0.43
27
133
65
422
1.57
2.95
3.5
3.5
2108.40
3605.63
u/ml
0.21
58
366
108
783
1.42
2.88
1.4
1.5
—
—
—
0
0
257
2124
1.27
2.85
1.9
1.7
96154277.17
23844857.15
pmol/l
0.46
208
1774
44
261
1.71
2.84
1.2
1.2
—
—
—
0
0
22
103
2.16
2.82
1.0
1.1
—
—
—
0
0
43
254
1.72
2.81
1.6
2.0
3.84
4.34
iu/l
0.09
16
93
19
84
2.28
2.78
7.1
5.4
231.72
37.90
u/ml
—
6
33
44
263
1.70
2.77
1.2
1.2
—
—
—
0
0
39
226
1.75
2.73
1.6
2.2
1780.85
4909.40
u/l
—
8
85
36
204
1.79
2.72
1.4
1.3
—
—
—
0
0
36
204
1.79
2.72
1.4
1.3
—
—
—
0
0
32
176
1.84
2.66
1.6
1.2
327.35
277.22
u/ml
0.27
20
98
326
2794
1.24
2.61
4.7
4.5
23.72
20.99
%
2.42
163
1344
50
315
1.62
2.59
1.5
1.5
0.02
0.09
iu/ml
—
9
52
45
278
1.65
2.53
2.6
1.7
—
—
—
0
0
7
16
4.40
2.47
1.0
1.2
1.95
1.83
umol/24h
—
7
16
223
1842
1.26
2.46
1.4
1.3
38.97
32.00
iu/ml
0.24
58
576
51
328
1.58
2.45
1.5
1.5
291.40
275.94
ug/g
0.19
30
201
87
628
1.42
2.41
1.2
1.2
127.36
136.13
u/ml
0.07
29
257
45
283
1.62
2.37
1.7
1.2
—
—
—
0
0
51
331
1.57
2.36
1.8
1.7
—
—
—
0
0
152
1202
1.31
2.36
2.7
2.4
128.61
122.50
ug/g
0.06
122
972
13
52
2.52
2.36
1.6
1.5
—
—
—
0
0
13
52
2.52
2.36
1.6
1.5
—
—
—
0
0
43
268
1.63
2.35
1.3
1.3
—
—
—
0
0
149
1176
1.31
2.35
1.8
1.8
1.62
1.51
%
0.51
131
1016
41
255
1.63
2.27
1.7
1.6
—
—
—
0
0
99
742
1.37
2.21
1.6
1.7
—
—
—
0
0
93
692
1.38
2.18
2.3
2.5
34.85
18.42
au/ml
0.70
11
65
116
894
1.33
2.17
2.5
2.4
14.66
6.78
ug/l
0.76
101
804
86
633
1.39
2.15
1.2
1.4
53.69
49.33
au/ml
—
9
46
16
74
2.18
2.15
1.1
1.2
—
—
—
0
0
13
55
2.38
2.12
1.0
1.1
—
—
—
0
0
38
237
1.63
2.10
1.9
1.5
4496.32
185.73
e6/l
0.63
25
181
388
3447
1.20
2.09
6.0
5.5
2.47
2.38
ug/l
0.10
360
3123
17
82
2.09
2.07
1.1
1.1
—
—
—
0
0
54
367
1.50
2.07
6.2
3.9
25.20
24.91
mmol/l
0.22
48
349
29
169
1.74
2.05
2.1
1.4
175.22
166.89
au/ml
—
9
52
6
15
4.02
2.04
1.2
1.2
100.83
91.53
%
—
6
15
16
77
2.09
1.97
1.1
1.2
—
—
—
0
0
16
77
2.09
1.97
1.1
1.2
—
—
—
0
0
37
235
1.59
1.92
1.9
1.4
10.39
26.38
e6/l
0.53
23
173
18
92
1.97
1.90
1.1
1.2
—
—
—
0
0
13
60
2.18
1.78
2.2
1.5
8.93
6.58
ug/l
0.39
13
52
15
74
2.04
1.75
1.0
1.1
106.80
106.45
pmol/l
0.01
15
74
50
700
0.70
1.69
1.6
1.8
3.43
3.48
mmol/l
0.09
31
510
0
49
0.00
1.68
0.0
1.2
—
—
—
0
0
72
946
0.74
1.65
1.9
2.0
3.69
3.50
ratio
0.54
54
760
71
532
1.36
1.65
1.5
1.5
—
—
—
0
0
16
84
1.92
1.60
1.2
1.8
—
—
—
0
0
39
264
1.50
1.58
3.2
3.2
1.39
1.54
mmol/l
0.98
39
258
180
1528
1.21
1.56
1.4
1.5
—
—
—
0
0
10
44
2.28
1.55
1.1
1.2
—
—
—
0
0
44
308
1.45
1.52
1.2
1.3
—
—
—
0
0
60
447
1.36
1.47
1.8
2.0
1.67
2.20
ug/l
0.27
53
405
18
103
1.76
1.41
2.8
1.3
—
—
—
0
0
13
67
1.95
1.38
1.2
1.4
14.69
12.87
u/l
0.25
13
61
32
216
1.50
1.34
3.4
3.3
7.79
7.46
mmol/l
0.26
32
211
10
47
2.14
1.34
2.1
2.3
—
—
—
0
0
19
113
1.69
1.32
1.1
1.1
—
—
—
0
0
9
43
2.10
1.30
1.2
1.1
—
—
—
0
0
14
76
1.85
1.30
1.1
1.2
—
—
—
0
0
56
422
1.34
1.30
1.7
1.9
10.28
8.19
iu/ml
—
6
103
65
501
1.32
1.30
4.3
3.5
1.02
1.02
ratio
0.31
57
464
61
466
1.33
1.29
1.1
1.0
—
—
—
0
0
11
55
2.01
1.27
1.3
1.3
87.45
166.90
pmol/l
2.15
11
55
33
228
1.46
1.25
1.5
1.4
—
—
—
0
0
8
36
2.23
1.24
1.6
1.5
45.63
58.11
ug/l
—
8
36
21
131
1.61
1.24
1.1
1.7
—
—
—
0
0
132
1117
1.21
1.21
3.7
4.5
9.35
25.34
ug/l
1.18
100
940
35
247
1.43
1.20
1.3
1.2
—
—
—
0
0
56
428
1.33
1.20
1.3
1.3
—
—
—
0
0
101
1214
0.81
1.18
6.1
5.0
30.43
32.32
%
1.12
70
791
10
50
2.01
1.16
2.1
3.2
437.00
1125.14
u/ml
—
10
50
37
266
1.40
1.16
1.5
1.7
5978.78
14052.39
e6/l
1.58
23
191
20
126
1.60
1.15
1.5
1.4
1205.67
1891.12
e6/l
0.79
12
86
21
135
1.57
1.12
1.0
1.1
—
—
—
0
0
13
74
1.77
1.07
1.8
2.7
9.16
8.36
mmol/l
0.27
13
74
11
61
1.81
0.98
1.0
1.1
—
—
—
0
0
5
23
2.18
0.98
1.2
1.2
—
—
—
0
0
0
30
0.00
0.97
0.0
1.8
—
—
—
0
0
7
36
1.95
0.97
1.4
1.2
103.00
106.90
%
—
7
30
20
133
1.51
0.94
1.1
1.1
—
—
—
0
0
6
27
2.23
0.93
2.0
2.5
0.60
0.60
mmol/l
—
6
27
21
142
1.49
0.92
1.2
1.7
—
—
—
0
0
28
203
1.39
0.88
1.1
1.6
—
—
—
0
0
8
44
1.82
0.86
1.3
1.3
5.97
6.38
mmol/l
—
8
44
100
1158
0.85
0.82
13.9
6.9
—
—
—
0
0
23
163
1.42
0.82
2.1
3.0
—
2263.23
—
0
13
32
244
1.32
0.76
1.1
1.1
5.27
3.71
—
6
32
17
116
1.47
0.74
1.2
1.3
—
—
—
0
0
25
184
1.37
0.74
1.2
1.8
—
—
—
0
0
43
343
1.26
0.74
2.0
1.8
—
—
—
0
0
53
436
1.23
0.71
1.8
1.6
0.23
0.37
mg/l
1.42
22
204
38
302
1.27
0.68
1.3
1.2
—
19.18
—
0
10
7
42
1.67
0.68
1.0
1.0
—
—
—
0
0
19
261
0.72
0.68
1.6
1.5
—
—
—
0
0
30
232
1.30
0.66
1.3
1.2
—
6.44
—
0
16
95
831
1.16
0.66
2.2
2.0
—
—
—
0
0
10
62
1.62
0.65
2.0
1.8
—
—
—
0
0
10
62
1.62
0.65
1.2
1.7
—
—
—
0
0
35
437
0.79
0.65
3.1
2.0
—
—
—
0
0
14
96
1.46
0.61
2.3
3.2
14.14
11.68
index
—
7
60
13
88
1.48
0.60
1.8
1.5
—
—
—
0
0
0
20
0.00
0.60
0.0
7.5
—
10.35
—
0
20
0
20
0.00
0.60
0.0
1.4
—
—
—
0
0
15
105
1.43
0.60
1.1
1.3
—
—
—
0
0
0
22
0.00
0.59
0.0
2.3
—
2.30
—
0
10
11
72
1.53
0.59
1.5
1.5
95.45
83.36
umol/l
0.32
11
72
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
53
1.51
0.58
1.0
1.1
—
—
—
0
0
26
202
1.29
0.57
1.2
1.5
87.73
259.66
pmol/l
1.27
26
197
33
266
1.25
0.56
1.2
1.3
—
—
—
0
0
10
65
1.54
0.55
1.0
1.2
—
—
—
0
0
10
65
1.54
0.55
1.0
1.2
—
—
—
0
0
16
116
1.38
0.54
2.5
3.8
—
—
—
0
0
45
377
1.20
0.54
2.2
2.0
—
—
—
0
0
9
61
1.48
0.53
1.2
1.7
—
—
—
0
0
34
278
1.23
0.52
1.4
1.4
—
—
—
0
0
6
40
1.50
0.51
1.8
2.3
77.50
52.22
umol/l
—
6
34
10
144
0.69
0.49
1.3
1.5
0.85
1.16
ratio
—
5
90
10
144
0.69
0.49
1.3
1.5
1.11
1.23
ratio
—
5
90
10
144
0.69
0.49
1.3
1.5
0.89
0.97
ratio
—
5
90
31
253
1.23
0.48
1.1
1.3
107.74
230.40
miu/ml
2.37
11
117
10
143
0.70
0.48
1.3
1.5
—
—
—
0
0
30
245
1.23
0.47
1.0
1.1
1.18
4.61
eliau/ml
—
5
26
28
229
1.23
0.44
2.0
1.6
—
—
—
0
0
38
321
1.19
0.44
1.3
1.3
—
—
—
0
0
5
31
1.62
0.43
1.0
1.1
19.44
39.32
u/ml
—
5
31
5
31
1.62
0.43
1.2
1.4
7.93
9.25
ug/l
—
5
31
30
360
0.83
0.43
2.9
1.9
—
—
—
0
0
44
378
1.17
0.42
2.0
2.7
—
—
—
0
0
10
70
1.43
0.41
1.2
1.7
—
—
—
0
0
29
240
1.21
0.41
1.2
1.6
—
—
—
0
0
25
204
1.23
0.41
1.1
1.6
—
—
—
0
0
17
132
1.29
0.40
1.2
1.5
—
—
—
0
0
17
132
1.29
0.40
1.2
1.5
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
17
133
1.28
0.38
1.2
1.5
—
—
—
0
0
247
2348
1.07
0.38
5.3
4.1
1.02
1.02
kg/l
2.33
174
1581
9
67
1.35
0.38
2.4
1.9
—
—
—
0
0
8
112
0.71
0.37
1.4
1.7
—
—
—
0
0
14
107
1.31
0.37
4.7
2.6
—
—
—
0
0
84
764
1.11
0.37
2.1
1.9
—
—
—
0
0
8
114
0.70
0.37
2.1
1.6
—
—
—
0
0
18
144
1.25
0.35
1.8
1.6
—
—
—
0
0
14
108
1.30
0.35
1.4
1.4
230095.00
34935.53
e6/l
—
8
58
33
283
1.17
0.34
1.2
1.7
—
—
—
0
0
6
44
1.37
0.34
1.2
1.2
—
—
—
0
0
143
1342
1.08
0.33
1.4
1.5
—
—
—
0
0
6
47
1.28
0.32
1.0
1.3
5.67
9.74
mm/h
—
6
47
17
137
1.24
0.32
1.2
1.5
—
—
—
0
0
7
55
1.27
0.30
1.1
1.2
—
—
—
0
0
20
166
1.21
0.30
1.2
1.6
—
—
—
0
0
17
139
1.23
0.29
1.2
1.5
—
—
—
0
0
31
272
1.14
0.26
1.1
1.7
—
—
—
0
0
9
75
1.20
0.25
1.1
1.2
—
—
—
0
0
9
77
1.17
0.24
1.6
1.5
62.05
51.77
ug/l
—
9
77
10
79
1.27
0.22
1.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
8
103
0.78
0.21
1.3
1.8
—
—
—
0
0
11
89
1.24
0.21
1.2
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
17
145
1.18
0.20
1.3
1.1
—
23.80
—
0
5
6
49
1.23
0.20
2.3
4.5
—
—
—
0
0
6
52
1.15
0.19
1.5
3.3
0.33
1.15
%
—
6
52
19
166
1.15
0.18
1.1
1.1
18.50
17.37
au/ml
—
7
44
7
60
1.17
0.18
1.7
3.3
0.86
0.90
index
—
7
60
19
215
0.88
0.16
3.2
3.8
22.30
27.89
mg/l
—
10
146
32
292
1.10
0.16
5.5
3.9
3.97
3.91
mmol/l
0.20
32
287
16
139
1.15
0.16
1.3
1.5
—
—
—
0
0
6
77
0.78
0.15
1.2
1.0
241.00
278.86
mg/l
—
6
71
8
98
0.81
0.13
1.6
1.6
—
—
—
0
0
11
94
1.17
0.13
1.0
1.1
—
—
—
0
0
31
334
0.93
0.12
1.1
1.2
0.92
0.90
g/l
0.19
31
334
11
96
1.15
0.10
2.2
1.8
—
—
—
0
0
5
45
1.11
0.10
1.0
1.1
—
—
—
0
0
5
46
1.09
0.09
3.6
1.3
—
—
—
0
0
15
136
1.10
0.08
1.1
1.1
0.06
2.44
u/ml
—
9
68
6
57
1.05
0.08
1.2
2.5
—
—
—
0
0
30
318
0.94
0.08
1.1
1.2
1.51
1.53
g/l
0.11
30
318
5
60
0.83
0.08
1.0
1.4
20.80
28.22
umol/l
—
5
55
7
64
1.09
0.08
1.1
1.2
—
—
—
0
0
7
64
1.09
0.08
1.3
2.3
204.57
238.33
e6/l
—
7
55
9
85
1.06
0.07
1.0
1.0
—
—
—
0
0
15
162
0.92
0.06
1.7
1.5
—
—
—
0
0
13
119
1.09
0.06
3.9
2.7
1.18
1.20
mmol/l
1.06
13
119
20
212
0.94
0.05
1.1
1.2
—
310.67
—
0
15
13
121
1.08
0.03
3.9
2.7
104.92
105.50
mmol/l
0.19
13
121
13
121
1.08
0.03
3.9
2.7
3.92
4.03
mmol/l
0.67
13
121
12
112
1.07
0.03
1.1
1.1
—
—
—
0
0
17
163
1.04
0.01
1.1
1.1
0.31
1.74
u/ml
1.55
11
90
10
94
1.06
0.01
1.2
1.6
—
—
—
0
0
10
94
1.06
0.01
1.2
1.6
—
—
—
0
0
10
94
1.06
0.01
1.2
1.6
—
—
—
0
0
13
136
0.96
0.00
1.2
1.1
1.52
1.53
g/l
0.01
13
126
31
307
1.01
0.00
1.5
1.4
—
—
—
0
0
5
49
1.02
0.00
1.4
1.1
608.60
1487.88
miu/ml
—
5
49
0
8
0.00
-0.00
0.0
1.5
—
12.38
—
0
8
8
79
1.01
-0.00
1.8
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
0.09
—
0
7
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
2.67
—
0
6
6
67
0.89
-0.00
1.3
2.2
382.67
590.52
e6/l
—
6
54
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
9
96
0.94
-0.00
1.6
1.1
—
70.43
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYPERALDO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALDO | 1.424 [1.23, 1.65] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.123 |
During the follow-up period (1.1.1998 — 31.12.2019), 414 out of 2277 females with E4_HYPERALDO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALDO | 1.218 [1.05, 1.41] | 0.009 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 357 out of 2005 males with E4_HYPERALDO died.
Mortality risk
Mortality risk for people of age
years, who have E4_HYPERALDO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.081% | 0.205% |
| 5 | 0.68% | 1.319% |
| 10 | 2.096% | 3.219% |
| 15 | 3.905% | 6.3% |
| 20 | 7.079% | 10.338% |
Relationships between endpoints
↥Index endpoint: E4_HYPERALDO – Hyperaldosteronism
GWS hits: 5
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data